FAP, June 2 / PRNewswire-FirstCall-Asianet /-- Xuantai Pharmaceutical announced that the company has received notification from the US Food and Drug Administration (FDA) that the company's application for a new drug (ANDA) for Pregabalin sustained-release tablets has been formally approved by the US FDA.